Die Posttraumatische Belastungsstörung - Teil 2: Kosten, Komorbiditäten und Therapie

Zusammenfassung

Die Posttraumatische Belastungsstörung (PTBS) hat aufgrund ihres häufigen Vorkommens neben der medizinischen auch eine große soziale und wirtschaftliche Bedeutung. Nicht nur die medizinische Behandlungsnotwendigkeit, sondern auch volkswirtschaftliche Gesichtspunkte verlangen nach einer effizienten Therapie der Betroffenen. Schätzungen von direkten und indirekten Folgekosten der PTBS in den USA, bewegen sich, nicht zuletzt als Folge der Ereignisse vom 11. Sept. 2001, im mehrstelligen Milliarden-Dollar-Bereich. Die Behandlung der PTBS gestaltet sich aufgrund von häufigen komorbid auftretenden Erkrankungen schwierig. Die Begleiterkrankungen sind mannigfaltig und decken den gesamten Bereich psychischer Erkrankungen ab. Die nosologische Eigenständigkeit der PTBS wird durch vielfältige organische Befunde aus der Elektrophysiologie und der funktionellen Bildgebung belegt. Ein sich mittlerweile aus vielen Richtungen abzeichnendes organisches Korrelat und eine Vielzahl von Verhaltensauffälligkeiten stellen weitere Ansatzpunkte für eine adäquate Therapie dar, die auf das Individuum abgestimmt und in einem integrativen Ansatz sowohl aus pharmakologischen als auch aus psychotherapeutischen Komponenten bestehen sollte.

Abstract

Besides a huge impact on psychiatric burden of disease, post-traumatic stress disorder (PTSD) is of immense socioeconomic importance. Not only medical, but also economical aspects demand an effective treatment of PTSD: direct and indirect costs of PTSD in the United States of America are estimated several billion dollars. Due to frequent co-morbidities, PTSD therapy proves to be complex and difficult. Co-morbid diseases are numerous and cover almost the whole field of psychiatry. The delineation of PTSD as a distinct nosological entity is however meanwhile substantiated by various findings generated by the means of multimodal neuroimaging, e. g. electrophysiological or functional imaging techniques. Converging lines of evidence, arguing for an organic correlate of PTSD, and widespread behavioural disturbances provide a further rationale for an adequate treatment of PTSD. This should be individually tailored for every patient and include both pharmacological as well as cognitive-behavioural methods to provide a modern, integrative approach to meet the requirements of this complex disease.

Posttraumatische Belastungsstörung - PTBS - PTSD - Therapie - Kosten - Ökonomie - Komorbide Erkrankungen - Pharmakotherapie - Kognitiv-behaviorale Therapie - Debriefing - Psychotherapie

Posttraumatic stress disorder - PTSD - therapy - costs - economy - co-morbid disorders - pharmacotherapy - cognitive-behavioural therapy - debriefing - psychotherapy

Literatur

• 1 Statistisches Bundesamt in Wiesbaden .Die Gesundheitsberichterstattung des Bundes im Auftrag des Bundesministeriums für Bildung und Forschung. www.gbe-bund.de
• 2 Frommberger U, Stieglitz R D, Nyberg E, Schlickewei W, Kuner E, Berger M. Prediction of posttraumatic stress disorder by immediate reactions to Trauma: a prospective study in road traffic accident victims.  Eur Arch Psychiatry Clin Neurosci. 1998;  248 316-321
• 3 Schnyder U. Die psychosozialen Folgen schwerer Unfälle. Darmstadt: Steinkopf 2000
• 4 Miller N E, Magruder K M. Cost-Effectiveness of psychotherapy. New York: Oxford University Press 1999: Chapter 24, Jaycox LH, Foa EB, S. 259-259
• 5 Suchtjahrbuch. Deutschland 2000
• 6 Kulka R A, John A, Fairbank B. Trauma and the Vietnam War generation: Report of findings from the National Vietnam Veterans, Readjustment Study. New York: Brunner/Mazel 1990
• 7 Koss M P, Koss P G, Woodruff W J. Deleterious effects of criminal victimization on woman's health and medical utilization.  Arch Intern Med. 1991;  151 342-347
• 8 Walker E A, Unutzer J, Rutter C. Costs of health care use by woman HMO members with a history of childhood abuse and neglect.  Arch Gen Psychiatry. 1999;  56 609-613
• 9 New M, Berliner L. Mental health service utilisation by victims of crime.  J Trauma Stress. 2000;  13 693-707
• 10 Kessler R C, Frank R G. The impact of psychiatric disorders on work loss days.  Psychol Med. 1997;  27 861-873
• 11 Kessler R C. Posttraumatic Stress Disorder: The Burden to the Individual and to Society.  J Clin Psychiatry. 2000;  61 (suppl 5) 4-12
• 12 Miller T R, Cohen M A, Wiesrma B. Victim costs and consequences: a new look. Washington DC: United States Department of Justice, National Institute of Justice. Research Report 1996
• 13 Duncan R D, Saunsers B E, Kilpatrick D G, Rochelle F. Childhood physical assault as a risk factor for PTSD, depression and substance abuse: Findings form a national survey.  Am J Orthopsych. 1996;  66 437-448
• 14 Kessler R C, Sonnega A, Bromet E. Posttraumatic stress disorder in the National Comorbidity Survey.  Arch Gen Psychiatry. 1995;  52 1048-1060
• 15 Breslauf N, Davis G C, Andreski P. Traumatic events and posttraumatic stress disorder in an urban population of young adults.  Arch Gen Psychiatry. 1991;  48 216-222
• 16 Deering C G, Glover S G, Ready D. Unique patterns of comorbidity in post traumatic stress disorder from different sources of trauma.  Compr Psychiatry. 1996;  37 336-346
• 17 Gibson L E, Holt J C, Fondacaro K M, Tang T S, Powell T A, Turbitt E L. An examination of antecedent traumas and psychiatric comorbidity among male inmates with PTSD.  Journal of Traumatic Stress. 1999;  12 473-484
• 18 Kessler R C, Borges G, Walters E E. Prevalence of and risk factors for lifetime suicide attempts in the national comorbidity survey.  Arch Gen Psychiatry. 1999;  56 617-626
• 19 Ferrada-Noli M, Asberg M, Ormstad K, Lundin T, Sundbom E. Suicidal behavior after severe trauma. Part 1: PTSD diagnosis, psychiatric comorbidity and assessments of suicidal behavior.  Journal of Traumatic Stress. 1998;  11 103-112
• 20 Acinero R, Kilpatrick D G, Resnick H, Saunders B, De Arellano M, Best C. Assault, PTSD, family substance use and depression as risk factors for cigarette use in youth: Findings from the national survey of adolescents.  Journal of Traumatic Stress. 2000;  13 381-396
• 21 Brown P J, Stout R L, Gannon-Rowley J. Substance use disorder-PTSD comorbidity. Patients'perceptions of symptom interplay and treatment issues.  Journal of Substance Abuse and its Treatment. 1998;  15 445-448
• 22 Yehuda R. Risk factors for PTSD. Washington DC, London, England: American Psychiatric Press, Inc 1999
• 23 Zlotnick C, Warshaw M, Shea M T, Allsworth J. Chronicity in PTSD and predictors of course of comorbid PTSD in patients with anxiety disorders.  J of Traumatic Stress. 1999;  12 89-99
• 24 Maes M, Delmeire L, Mylle J, Altamura C. Risk and preventive factors of PTSD: Alcohol consumption and intoxication prior to a traumatic event diminishes the relative risk to develop PTSD in response to that trauma.  J Affect Disord. 2001;  63 113-121
• 25 Deahl M P, Gillham A B, Thomas J. Psychological sequelae following the Gulf War. Factors associated with subsequent morbidity and the effectiveness of psychological debriefing.  Br J Psychiatry. 1994;  165 (2) 60-65
• 26 Deahl M P, Srinivasan M, Jones N. Evaluating psychological debriefing: are we measuring the right outcomes?.  J Trauma Stress. 2001;  14 (3) 527-529
• 27 Carol S, Fullerton Ph D, Robert J. Debriefing Following Trauma.  Psychiatric Q. 2000;  71 259-276
• 28 Suzanna R, Jonathan B, Simon W. Psychological debriefing for preventing PTSD.  Cochrane Database Syst Rev. 2001;  (3) CD000560
• 29 Horowitz M J. Stress response syndromes. Character style and dynamic psychotherapy.  Arch Gen Psychiatry. 1974;  31 768-781
• 30 Reist C, Kauffmann C D, Haier R J. A controlled trial of desipramine in 18 men with PTSD.  Am J Psychiatry. 1989;  146 513-516
• 31 Davidson J RC, Kudler H, Smith R. Treatment of PTSD with amitriptyline and placebo.  Arch Gen Psychiatry. 1990;  47 259-266
• 32 Kosten T R, Frank J B, Dan E. Pharmacotherapy for PTSD using phenelzine or imipramine.  J Nerv Ment Dis. 1991;  179 366-370
• 33 Van der Kolk B A, Dreyfull D, Michaels M. Fluoxetine in PTSD.  J Clin Psychiatry. 1994;  55 517-522
• 34 Marshall R D, Schneider F R, Knight C BG. An open trial of Paroxetine in patients with combat-related chronic PTSD.  J Clin Psychopharmacol. 1998;  18 10-18
• 35 Brady K T, Sonne S C, Roberts J M. Sertraline in the treatment of rape victims with PTSD and alcohol dependence.  J Clin Psychiatry. 1995;  56 502-505
• 36 Kline N A, Dow B M, Brown S A. Sertraline efficacy in depressed combat veterans with PTSD.  Am J Psychiatry. 1994;  151 621
• 37 DeBoer M, Op den Velde W, Falger P J. Fluvoxamine treatment for chronic PTSD: A pilot study.  Psychother Psychosom. 1992;  57 158-163
• 38 Marmar C R, Schoenfeld F, Weiss D S. Open trial of fluvoxamine treatment for combat-related PTSD.  J Clin Psychiatry. 1996;  57 (Suppl.) 66-72
• 39 Baker D G, Diamond B I, Gillette G. A double-blind, randomized, placebo-controlled, multicenter study of brofaromine in the treatment of PTSD.  Psychopharmacology. 1995;  122 386-389
• 40 Katz R J, Lott M H, Arbus P. Pharmacotherapy of PTSD with a novel psychotropic.  Anxiety. 1995;  1 169-174
• 41 Neal L A, Sapland W, Fox C. An open trial of moclobemide in the treatment of PTSD.  Int Clin Psychopharmacol. 1997;  12 231-315
• 42 Lowenstein R J, Hornstein N, Farber B. Open trial of clonazepam in the treatment of post traumatic stress symptoms in multiple personality disorder.  Dissociation. 1988;  1 2-12
• 43 Kitchner I, Greenstein R. Low dose lithium carbonate in the treatment of PTSD.  Mil Med. 1985;  150 378-381
• 44 Van der Kolk B A. Psychopharmacological issues in PTSD.  Hosp Comm Psychiatry. 1983;  34 683-691
• 45 Forster P L, Schoenfeld F B, Marmar C R. Lithium for irritability in PTSD.  J Traum Stress. 1995;  8 143-149
• 46 Lipper S, Hammett E B, Davidson J RT. Preliminary study of carbamazepine in PTSD.  Psychosomatics. 1986;  27 849-854
• 47 Looff D, Grimley P, Kuller F. Carbamazepine for PTSD.  J Am Acad Child Adolesc Psychiatry. 1995;  34 703-704
• 48 Wolf M E, Alavi A, Mosnaim A D. PTSD in Vietnam Veterans: Clinical and EEG findings; possible therapeutic effects of carbamazepine.  Biol Psychiatry. 1988;  23 642-644
• 49 Donovan S J, Susser E S, Nunes E V. Divalproex treatment of disruptive adolescents: A report on 10 cases.  J Clin Psychiatry. 1997;  58 12-15
• 50 Fesler F A. Valproate in combat-related PTSD.  J Clin Psychiatry. 1991;  52 361-364
• 51 Szymansky H V, Olympia J. Divalproex In PTSD.  Am J Psychiatry. 1991;  148 1086-1087
• 52 Kolb L C, Burris B C, Griffith S. Propranolol and clonidine in the treatment of PTSD of war: Psychological and biological sequelae. Washington/DC, London: American Psychiatric Press 1984: pp 98-105
• 53 Hamner M B. Clozapine treatment for a veteran with comorbid psychosis and PTSD.  Am J Psychiatry. 1996;  60 309-318
• 54 Solomon S D, Gerrity E T, Muff A M. Efficacy of treatments for PTSD. An empirical review.  JAMA. 1992;  286 633-638
• 55 Ebbinghaus R, Bauer M, Riebe S. Behandlung der PTBS.  Fortschr Neurol Psychiat. 1996;  64 433-443
• 56 Shalev A Y, Bonne O, Eth S P. Treatment of PTSD: A review.  Psychosom Med. 1996;  58 165-182
• 57 Gerrity E T, Solomon S D. The treatment of PTSD and related stress disorders. Current research and clinical knowledge. In: Marsella AJ, Friedmann M, Spain B. Ethnocultural Aspects of PTSD. Washington, DC: American Psychological Association 1996: 87-102
• 58 Foa E B, Meadows E A. Psychosocial treatments for PTSD. A critical review.  Ann Rev Psychol. 1997;  48 449-480
• 59 Sherman J J. Effects of psychotherapeutic treatments for PTSD: a meta-analysis of controlled clinical trials.  J Trauma Stress. 1998;  11 413-435
• 60 van Etten M L, Taylor S. Comparative efficacy of treatments for PTSD: a meta-analysis.  J Clin Psychol Psychother. 1998;  5 126-144
• 61 Shepherd J, Stein K, Milne R. EMDR in the treatment of PTSD: a review of an emerging therapy.  Psychol Med. 2000;  30 863-871